Clinical Trials Logo

Diabetic Macular Edema (DME) clinical trials

View clinical trials related to Diabetic Macular Edema (DME).

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04697758 Terminated - Clinical trials for Diabetic Macular Edema (DME)

Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema

CONGO
Start date: December 10, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study is an open-label, dose-escalating, 48-week study assessing the safety, tolerability, bioactivity and duration of action of a single intravitreal injection of 0.1 mg, 0.25 mg, or 0.5 mg AXT107 in approximately 18 subjects (up to 6 subjects per dose) with Diabetic Macular Edema (DME).

NCT ID: NCT02080091 Terminated - Clinical trials for Diabetic Macular Edema (DME)

Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Therapies

ILUMINATE
Start date: December 2013
Phase: N/A
Study type: Observational

This observational study aims to assess the safety and effect of Iluvien® in DME patients considered insufficiently responsive to available therapies in a real life setting in Germany.

NCT ID: NCT00936520 Terminated - Clinical trials for Diabetic Macular Edema (DME)

SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy

Start date: August 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of SAR 1118 within the anterior and posterior chamber of the eye and plasma in subjects undergoing elective vitrectomy when treated with escalating concentrations of the study drug for approximately 1 week.